A method for obtaining a salt with a general formula: R.sub.xNI, wherein: R.sub.xN is an organic cation (R.sub.xN.sup.+), R represents substituents (R−) independently selected from a group consisting of organic substituents: R.sup.1−, R.sup.2—, R.sup.3— and hydrogen (H—), x is a number of the substituents R— directly linked with the nitrogen (N) atom in the organic cation R.sub.xN.sup.+, wherein x is 3 or 4, I is an iodide anion (I.sup.−). The method comprises: preparing a reaction mixture comprising the steps of: synthesizing hydrogen iodide (HI) in situ by mixing molecular iodine (I.sub.2) with formic acid (COOH) in a molar ratio of molecular iodine (I.sub.2): formic acid (COOH) of no less than 1.01:1, in a solvent medium, introducing into the solvent medium a compound being a donor of organic cation R.sub.xN.sup.+ in an amount providing the molar ratio of the donor of organic cation R.sub.xN.sup.+: molecular iodine (I.sub.2) of no less than 1.01:1, and maintaining the reaction mixture at a temperature of not less than 20° C. for the time necessary to obtain the reaction product being the salt with the general formula R.sub.xNI. The obtained product is a substrate for synthesis of perovskites.

The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-5N-(methyl-d3)pyridazine-3-carboxamide of the formula:

##STR00001##

Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.

The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-5N-(methyl-d3)pyridazine-3-carboxamide of the formula:

##STR00001##

Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.

The present disclosure discloses a quantum dot and a preparation method thereof, the method comprises a plurality of following steps: preparing a quantum dot solution; preparing an ion-containing organic ligand precursor; adding the ion-containing organic ligand precursor into the quantum dot solution, and making a surface-modification to the quantum dots, before obtaining the quantum dots having the surfaces modified; or providing a quantum dot solution; providing an ion-containing organic ligand precursor; mixing the ion-containing organic ligand precursor and the quantum dot solution, to make a ligand exchanging, before centrifuging and obtaining the quantum dots having the ligand exchanged.

The present disclosure relates to novel processes for the preparation of compounds useful as stimulators of soluble guanylate cyclase (sGC). These processes are amenable to large scale preparation and produce stable 3-(2-pyrimidinyl)pyrazoles of Formula (I), including Compound (I), Compound (IA) and Compound (IB), in high purity and yields. The present invention has the additional advantage of facile reaction conditions, amenable to scale up for large scale manufacturing. The disclosure also provides novel intermediates useful in the preparation of said compounds.

The present disclosure relates to novel processes for the preparation of compounds useful as stimulators of soluble guanylate cyclase (sGC). These processes are amenable to large scale preparation and produce stable 3-(2-pyrimidinyl)pyrazoles of Formula (I), including Compound (I), Compound (IA) and Compound (IB), in high purity and yields. The present invention has the additional advantage of facile reaction conditions, amenable to scale up for large scale manufacturing. The disclosure also provides novel intermediates useful in the preparation of said compounds.

##STR00001##

Provided is a method for manufacturing diisocyanate and an optical lens in which, during the manufacture of diisocyanate from diamine via diamine hydrochloride, use is made of an aqueous hydrochloric acid solution and an organic solvent instead of hydrogen chloride gas and solid-phase triphosgen instead of phosgen gas while reaction conditions are controlled, whereby the diisocyanate of high quality can be manufactured at excellent yield, with the causation of less environmental problems.

Provided is a method for manufacturing diisocyanate and an optical lens in which, during the manufacture of diisocyanate from diamine via diamine hydrochloride, use is made of an aqueous hydrochloric acid solution and an organic solvent instead of hydrogen chloride gas and solid-phase triphosgen instead of phosgen gas while reaction conditions are controlled, whereby the diisocyanate of high quality can be manufactured at excellent yield, with the causation of less environmental problems.

A compound having the following structure: ##STR00001##
or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, Parkinson's disease, levodopa-induced dyskinesia, Huntington's disease, Gilles de la Tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, Alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis.

A compound having the following structure: ##STR00001##
or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, Parkinson's disease, levodopa-induced dyskinesia, Huntington's disease, Gilles de la Tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, Alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis.